Abstract
Methods Six hundred and ten moderate-to-severe SAR patients (≥12 yrs) were randomized into a double-blind, PLAcontrolled, 14-day, parallel-group, trial (NCT00660517) to MP29-02*, AZE, FP or PLA nasal sprays (1 spray/ nostril bd; daily dose: AZE=548μg; FP=200μg) [1]. Change from baseline (CFB) in reflective total of 7 symptom scores (rT7SS; AM + PM, max=42) was assessed post-hoc. CFB in rT7SS and each nasal (congestion, itching, rhinorrhea, sneezing) and ocular symptom (itching, redness, watering; max=6 each) was assessed over time.
Highlights
The efficacy of MP29-02* in providing overall nasal and ocular symptom relief vs AZE, FP or placebo (PLA) has been assessed
Level of congestion relief provided by MP29-02* on Day 2 (-0.77) was not achieved before Day 6 and Day 9 for FP and AZE, respectively
MP29-02* provided significantly superior ocular itching relief vs FP from Day 2 and vs AZE from Day 3; the ocular itch relief provided by MP29-02* on Day 2 (-0.77) was not achieved before Day 10 for FP-patients
Summary
A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies. Peter Hellings1*, Claus Bachert, Ralph Mösges, Glenis Scadding, Ullrich Munzel, Wytske Fokkens. From The 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015) Stockholm, Sweden. From The 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015) Stockholm, Sweden. 19-21 February 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
